Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

(2018) Amanda Balboni Iniguez et al.   CANCER CELL

Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm

(2018) K. Tsafou et al.   JOURNAL OF MOLECULAR BIOLOGY

Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma

(2018) Bárbara Kunzler Souza et al.   MOLECULAR NEUROBIOLOGY

EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

(2018) Aparna Gorthi et al.   NATURE

Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue

(2016) Maria E. Gierisch et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility

(2016) Samantha G. Pattenden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma

(2016) Ziyan Y. Pessetto et al.   Oncotarget

Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors

(2015) E. Hedrick et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing

(2015) Saravana P. Selvanathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1

(2015) Eleni M. Tomazou et al.   Cell Reports

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

(2015) Kyungsoo Ha et al.   Oncotarget

EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma

(2014) Nicolò Riggi et al.   CANCER CELL

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773

(2014) M. Michelagnoli et al.   PEDIATRIC BLOOD & CANCER

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Outcome for Children with Metastatic Solid Tumors over the Last Four Decades

(2014) Stephanie M. Perkins et al.   PLoS One

Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats

(2014) Xuezhi Yang et al.   XENOBIOTICA

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

(2013) Srikanth R. Ambati et al.   Molecular Oncology

Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines

(2013) William A. May et al.   PLoS One

Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group

(2012) Richard B. Womer et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone deacetylases and cancer

(2012) Bruna Barneda-Zahonero et al.   Molecular Oncology

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

(2012) S. R. Stecklein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group

(2011) Sylvain Baruchel et al.   EUROPEAN JOURNAL OF CANCER

Entinostat for treatment of solid tumors and hematologic malignancies

(2011) Jeffrey Knipstein et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Chemotherapy in Ewing′s sarcoma

(2010) Gauri Kapoor et al.   Indian Journal of Orthopaedics

Ewing's sarcoma

(2010) Naomi J Balamuth et al.   LANCET ONCOLOGY

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

(2009) Hayriye V Erkizan et al.   NATURE MEDICINE

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group

(2008) Steven G. DuBois et al.   PEDIATRIC BLOOD & CANCER

Induction of drug metabolism: Species differences and toxicological relevance

(2008) Mark J. Graham et al.   TOXICOLOGY